Department of Medicine/Dermatology, University of Washington, Seattle, Washington.
Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington.
J Am Acad Dermatol. 2014 Apr;70(4):637-643. doi: 10.1016/j.jaad.2013.11.031. Epub 2014 Feb 9.
The effects of primary tumor size on nodal involvement and of number of involved nodes on survival have not, to our knowledge, been examined in a national database of Merkel cell carcinoma (MCC).
We sought to analyze a retrospective cohort of patients with MCC from the largest US national database to assess the relationships between these clinical parameters and survival.
A total of 8044 MCC cases in the National Cancer Data Base were analyzed.
There was a 14% risk of regional nodal involvement for 0.5-cm tumors that increased to 25% for 1.7-cm (median-sized) tumors and to more than 36% for tumors 6 cm or larger. The number of involved nodes was strongly predictive of survival (0 nodes, 76% 5-year relative survival; 1 node, 50%; 2 nodes, 47%; 3-5 nodes, 42%; and ≥6 nodes, 24%; P < .0001 for trend). Younger and/or male patients were more likely to undergo pathological nodal evaluation.
The National Cancer Data Base does not capture disease-specific survival. Hence, relative survival was calculated by comparing overall survival with age- and sex-matched US population data.
Pathologic nodal evaluation should be considered even for patients with small primary MCC tumors. The number of involved nodes is strongly predictive of survival and may help improve prognostic accuracy and management.
据我们所知,在梅克尔细胞癌(MCC)的国家数据库中,尚未检查原发肿瘤大小对淋巴结受累的影响,以及受累淋巴结数量对生存的影响。
我们试图分析美国最大的国家数据库中 MCC 患者的回顾性队列,以评估这些临床参数与生存之间的关系。
对国家癌症数据库中的 8044 例 MCC 病例进行了分析。
0.5cm 肿瘤的区域淋巴结受累风险为 14%,而 1.7cm(中位大小)肿瘤的受累风险增加到 25%,6cm 或更大的肿瘤的受累风险超过 36%。受累淋巴结的数量与生存密切相关(0 个淋巴结,5 年相对生存率为 76%;1 个淋巴结,50%;2 个淋巴结,47%;3-5 个淋巴结,42%;≥6 个淋巴结,24%;趋势 P<0.0001)。年轻和/或男性患者更有可能接受病理淋巴结评估。
国家癌症数据库无法捕获疾病特异性生存情况。因此,通过将总体生存与年龄和性别匹配的美国人群数据进行比较,计算相对生存率。
即使对于患有小的原发性 MCC 肿瘤的患者,也应考虑进行病理淋巴结评估。受累淋巴结的数量与生存密切相关,可能有助于提高预后准确性和管理。